Allucent

Allucent is a global contract research organization (CRO) established in 2022 through the merger of several companies with extensive experience in drug development. The organization partners with small and mid-sized biopharma and biotech firms to expedite the delivery of innovative therapies, particularly in oncology, rare diseases, and cell and gene therapies. Allucent operates in over 75 countries, providing tailored solutions that combine the scale of large CROs with specialized expertise. The company offers a comprehensive suite of drug development services, including regulatory consulting, clinical operations, biometrics, and clinical pharmacology. Allucent has conducted over 1,015 clinical trials, primarily focused on oncology, and manages more than 825 regulatory submissions annually. With a workforce of over 1,300 employees and a commitment to operational efficiency, Allucent supports the development of over 650 drugs and emphasizes adaptability to meet client milestones. The company is headquartered in Cary, North Carolina, and has offices across the Americas, Europe, and Asia.